Emerging drugs and combinations to treat multiple myeloma

In the past few years, multiple targeted therapies and immunotherapies including second generation immunomodulatory drugs (pomalidomide) and proteasome inhibitors (carfilzomib, ixazomib), monoclonal antibodies and checkpoint inhibitors were approved for the treatment of myeloma or entered advanced p...

Descripción completa

Detalles Bibliográficos
Autores principales: Larocca, Alessandra, Mina, Roberto, Gay, Francesca, Bringhen, Sara, Boccadoro, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601169/
https://www.ncbi.nlm.nih.gov/pubmed/28948001
http://dx.doi.org/10.18632/oncotarget.19269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601169/
https://www.ncbi.nlm.nih.gov/pubmed/28948001
http://dx.doi.org/10.18632/oncotarget.19269

Ejemplares similares